Eptacog alfa (activated)
NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as Novoseven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral hemorrhage | D002543 | — | 7 | 2 | — | — | 9 | ||
| Wounds and injuries | D014947 | T14.8 | — | 3 | 2 | — | 1 | 6 | |
| Factor vii deficiency | D005168 | D68.2 | 1 | 1 | 1 | — | 1 | 3 | |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | — | — | 1 | |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | 1 | — | — | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | 1 | — | — | 1 |
| Burns | D002056 | T30.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 3 | — | — | 4 | 7 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | — | — | — | 2 |
| Thrombasthenia | D013915 | D69.1 | 1 | 1 | — | — | — | 1 | |
| Severe dengue | D019595 | A91 | — | 1 | — | — | — | 1 | |
| Spinal fusion | D013123 | — | 1 | — | — | — | 1 | ||
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | — | — | — | — | 8 | ||
| Hemostasis | D006487 | 2 | — | — | — | — | 2 | ||
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPTACOG ALFA (ACTIVATED) |
| INN | eptacog beta (activated) |
| Description | NovoSeven (eptacog alfa (activated)) is a protein pharmaceutical. Eptacog alfa (activated) was first approved as Novoseven on 1996-02-23. It has been approved in Europe to treat factor VII deficiency, hemophilia a, hemophilia b, and thrombasthenia. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108334 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | AC71R787OV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Novoseven - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 916 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,647 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more